Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Biology, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
J Ovarian Res. 2019 Dec 6;12(1):120. doi: 10.1186/s13048-019-0588-z.
Ovarian cancer has the highest ratio of mortality among gynecologic malignancies. Chemotherapy is one of the most common treatment options for ovarian cancer. However, tumor relapse in patients with advanced tumor stage is still a therapeutic challenge for its clinical management.
Therefore, it is required to clarify the molecular biology and mechanisms which are involved in chemo resistance to improve the survival rate of ovarian cancer patients. Cancer stem cells (CSCs) are a sub population of tumor cells which are related to drug resistance and tumor relapse.
In the present review, we summarized the recent findings about the role of CSCs in tumor relapse and drug resistance among ovarian cancer patients. Moreover, we focused on the targeted and combinational therapeutic methods against the ovarian CSCs.
卵巢癌是妇科恶性肿瘤中死亡率最高的一种。化疗是卵巢癌最常见的治疗选择之一。然而,晚期肿瘤患者的肿瘤复发仍然是其临床管理的一个治疗挑战。
因此,有必要阐明参与化疗耐药的分子生物学和机制,以提高卵巢癌患者的生存率。癌症干细胞(CSC)是与耐药性和肿瘤复发相关的肿瘤细胞的一个亚群。
在本综述中,我们总结了最近关于 CSC 在卵巢癌患者肿瘤复发和耐药中的作用的研究结果。此外,我们还重点介绍了针对卵巢 CSC 的靶向和联合治疗方法。